Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

• Published in: European journal of cancer (1990) 1996-03, Vol.32 (3), p.413-416
• Main Authors: McClelland, R.A., Gee, J.M.W., Francis, A.B., Robertson, J.F.R., Blarney, R.W., Wakeling, A.E., Nicholson, R.I.
• Format: Article
• Language: English
• Subjects: Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; epidermal growth factor receptor; ErbB Receptors - metabolism; Estradiol - analogs & derivatives; Estradiol - pharmacology; Estrogen Antagonists - pharmacology; Female; Frozen Sections; Fulvestrant; human breast cancer; Humans; Immunohistochemistry; oestrogen receptor; Postmenopause; pure anti-oestrogens; Receptors, Estrogen - metabolism; Transforming Growth Factor alpha - metabolism; transforming growth factor-alpha; Tumor Cells, Cultured - drug effects; Tumor Cells, Cultured - metabolism
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)00517-X

Expression of oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and transforming growth factor-α (TGFα) proteins was assessed by immunocytochemistry on primary breast cancer specimens obtained before and following short-term (7-day) presurgical exposure to pure anti-oestrogen (7α- [9- (4,4,5,5,5-pentafluoropentylsulphinyl) nonyl] estra-1,3,5, (10)-triene-3,17 β-diol, ICI 182780) treatment and compared with no-treatment controls. Paired needle-core and mastectomy samples were obtained from 21 patients. Effects of ICI 182780 (10 −7M) on MCF7 breast cancer cell ER, EGFR and TGFα expression were also examined over 14 days. ER protein was significantly suppressed by ICI 182780 in vivo (P = 0.009) and comparative analysis of short term ICI 182780 effects in vitro, using ER-positive MCF7 cells, gave largely equivalent results. EGFR and TGFα protein levels were unaltered by treatment. ICI 182780 suppresses ER without a concomitant rise in either EGFR or TGFα.